We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Lipocalin 2 Proposed as Biomarker for Bacterial Meningitis

By LabMedica International staff writers
Posted on 05 Aug 2020
Print article
Image: The Quantikine ELISA Human Lipocalin-2/NGAL Kit is a solid phase sandwich ELISA that quantifies human Lipocalin-2/NGAL in serum, heparin plasma, saliva, and urine (Photo courtesy of R&D Systems).
Image: The Quantikine ELISA Human Lipocalin-2/NGAL Kit is a solid phase sandwich ELISA that quantifies human Lipocalin-2/NGAL in serum, heparin plasma, saliva, and urine (Photo courtesy of R&D Systems).
Central nervous system (CNS) infections cause significant mortality and morbidity worldwide. Common CNS infections include bacterial meningitis (BM) other than tuberculosis, viral encephalitis, tuberculous meningitis (TBM) and cryptococcal meningitis, but there are more than 100 documented infectious causes of CNS infections.

Clinical features are often insufficient to discriminate the likely cause and standard laboratory investigations identify the causative agent in less than 60% of cases. Critically, the clinical management of CNS infections varies according to its etiology. Therefore, rapid and accurate identification of the likely cause of the infection is essential to initiate appropriate therapy and improve patient outcome.

Scientists from the Oxford University Clinical Research Unit (Ho Chi Minh City, Vietnam) and their associates applied liquid chromatography tandem mass-spectrometry on 45 cerebrospinal fluid (CSF) samples from a cohort of adults with/without CNS infections to discover potential diagnostic biomarkers. They then validated the diagnostic performance of a selected biomarker candidate in an independent cohort of 364 consecutively treated adults with CNS infections admitted to a referral hospital in Vietnam.

Measurement of lipocalin 2 (LCN2) concentrations was performed on CSF samples and a subset of plasma samples of the study participants using monoclonal antibody based Quantikine ELISA kits (R&D Systems, Minneapolis, MN, USA) which costs around USD 10/test. CSF was analyzed as individual samples using proteomic platforms. MS/MS spectra were searched against the UniProt Homo Sapiens Reference proteome. Deamidation on asparagine and glutamine and oxidation on methionine were included as variable modifications.

The team identified LCN2 as a potential biomarker of BM other than tuberculous meningitis. The analysis of the validation cohort showed that LCN2 could discriminate BM from other CNS infections (including tuberculous meningitis, cryptococcal meningitis and viral/antibody-mediated encephalitis), with the sensitivity of 0.88, the specificity equaled 0.91 and the diagnostic odds ratio was 73.8. LCN2 outperformed other CSF markers (leukocytes, glucose, protein and lactate) commonly used in routine care worldwide. The combination of LCN2, CSF leukocytes, glucose, protein and lactate resulted in the highest diagnostic performance for BM (area under receiver-operating-characteristic-curve = 0.96).

The authors concluded that their results suggest that LCN2 is a sensitive and specific biomarker for discriminating BM from a broad spectrum of other CNS infections. A prospective study is needed to assess the diagnostic utility of LCN2 in the diagnosis and management of CNS infections. The study was published on July 10, 2020 in the journal Clinical Microbiology and Infection.

Related Links:
Oxford University Clinical Research Unit
R&D Systems


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.